European Treatment and Outcome Study score does not predict imatinib treatment response and outcome in chronic myeloid leukemia patients
Version of Record online: 23 JAN 2014
© 2013 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 105, Issue 1, pages 105–109, January 2014
How to Cite
Cancer Sci 105 (2014) 105–109
- Issue online: 24 JAN 2014
- Version of Record online: 23 JAN 2014
- Accepted manuscript online: 8 NOV 2013 11:23AM EST
- Manuscript Accepted: 5 NOV 2013
- Manuscript Revised: 25 OCT 2013
- Manuscript Received: 16 SEP 2013
- 10Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR. Rinsho Ketsueki 2009; 50: 481–7. (In Japanese)., , et al.
- 18EUTOS score is predictive of event-free survival, but not for progressive-free and overall survival in patients with early chronic phase chronic myeloid leukemia treated with imatinib: a single institute experience. Blood 2012; 120 (ASH abstract no. 1681)., , et al.
- 19Comparison of Sokal, Hasford and EUTOS scores in terms of long-term treatment outcome according to the risks in each model: a single center date analyzed in 255 early chronic phase chronic myeloid leukemia patients treated with frontline imatinib mesylate. Blood 2012; 120 (ASH abstract no. 2794)., , et al.
- 20The EUTOS score is highly predictive for clinical outcome and survival in Asian patients with early chronic phase chronic myeloid leukemia treated with imatinib. Blood 2012; 120 (ASH abstract no. 3758)., , et al.